Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans
Affordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a new KFF analysis of 2024 federal plan data.
View the Latest: Prescription Drugs
Filter
-
-
Insurer Strategies to Control Costs Associated with Weight Loss Drugs
Issue BriefAffordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a an analysis of 2024 federal plan data.
-
KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs
FeatureKFF’s latest Health Tracking Poll examines the public’s views and use of an an increasingly popular class of prescription drugs used for weight loss and to treat diabetes or prevent heart attacks or strokes. The poll finds 12% of adults report having taken one of these GLP-1 drugs, which include Ozempic, Webovy and Mounjaro. This includes 6% who say they are currently taking one of the drugs.
-
Poll: 1 in 8 Adults Say They’ve Taken a GLP-1 Drug, Including 4 in 10 of Those with Diabetes and 1 in 4 of Those with Heart Disease
News ReleaseAbout one in eight adults (12%) say they have taken one of an increasingly popular class of prescription drugs known as GLP-1s that are used for weight loss and to treat diabetes and reduce the risk of heart disease and stroke, a new KFF Health Tracking Poll finds.
-
Coverage of Sexual and Reproductive Health Services in Medicare
Issue BriefThis brief describes Medicare coverage of sexual and reproductive health services, including contraception, and compares that coverage with private insurance plans and Medicaid. These benefits are particularly relevant to nearly 1 million women of reproductive age (20-49) who are eligible for Medicare due to having a long-term disability.
-
Gross Medicare Spending on Ozempic and Other GLP-1s Is Already Skyrocketing – Even Though Medicare Cannot Cover The Drugs for Weight Loss
News ReleaseA KFF analysis shows that gross total Medicare spending on Ozempic and other similar drugs has increased dramatically in recent years – even though Medicare is explicitly prohibited by law from covering the drugs for obesity. That’s because Medicare now covers the drugs, known as GLP-1s, for other medically accepted indications, including to treat diabetes.
-
Medicare Spending on Ozempic and Other GLP-1s Is Skyrocketing
Policy WatchThis policy watch analyzes the latest data on Medicare Part D spending on GLP-1 drugs, initially approved to treat diabetes but in high demand as treatments for obesity, and shows how spending on these drugs has increased substantially in recent years.
-
FAQs on Prescription Drug Importation
Issue BriefThese FAQs address questions related to prescription drug importation, including the current status of importation proposals, details of Florida’s importation program recently authorized by the FDA, and concerns and challenges with this approach.
-
KFF Health Tracking Poll February 2024: Voters on Two Key Health Care Issues: Affordability and ACA
FeatureThis poll finds that inflation and health care affordability are the top issues voters want 2024 presidential candidates to discuss, as most rate the economy negatively. Adults worry most about affording unexpected medical bills and health care costs, and the Affordable Care Act remains popular despite partisan differences when it comes to its future.
-
KFF Health Tracking Poll: Economic Views and Experiences of Adults Who Struggle Financially
FeatureHalf of adults say they have difficulty affording monthly bills or are just able to afford household expenses without having money left over. These groups overwhelmingly rate the economy negatively and are more likely to want 2024 presidential candidates to discuss economic issues.